PLUS1
2.42
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.42 | 0.00 | 0.00 | 0.00 | 2.42 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.30 | 2.82 | 0.52 | 18.44% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.42 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 79.50M | 32.85M | $ -12.37M | -0.89 | - | 32.23M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/31/2020 | 17:51 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 3/31/2020 | 17:42 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/a) |
| 3/31/2020 | 16:52 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 3/30/2020 | 16:07 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/24/2020 | 09:20 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/24/2020 | 08:17 | Business Wire | Genprex Bolsters Board of Directors, Appoints Three.. |
| 3/23/2020 | 15:52 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.91 | 3.17 | 2.30 | 2.69 | 1,307,864 | -0.49 | -16.84% |
| 1 Month | 4.56 | 4.80 | 1.49 | 3.00 | 2,582,568 | -2.14 | -46.93% |
| 3 Months | 0.38 | 7.03 | 0.3111 | 3.03 | 8,315,750 | 2.04 | 536.84% |
| 6 Months | 0.82 | 7.03 | 0.231 | 2.83 | 4,149,222 | 1.60 | 195.12% |
| 1 Year | 1.61 | 7.03 | 0.231 | 2.81 | 2,101,279 | 0.81 | 50.31% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.14 | 1,115,813 | -2.27 | -48.4% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.14 | 1,115,813 | -2.27 | -48.4% |
Genprex Description
| Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
